Taiwan-based startup Leadgene Biosolutions has announced the expansion of its product portfolio following its strategic integration into Leadgene Biomedical. The expanded portfolio supports both early-stage cell line development and long-term metabolic research, enabling researchers to make more informed decisions earlier in their workflows.
For biopharmaceutical companies, Leadgene Biosolutions continues to advance its microbioreactor platform family with S.NEST® 2.0 and C.NEST® 2.0, designed for 96- and 24-well microplate-based cell line development and early-stage clone assessment.
By introducing controlled mixing at early stages where it has traditionally been difficult to implement, these platforms support faster and more consistent cell growth. In 24-well formats, a dedicated mixing mode enables higher cell densities, allowing more process-relevant experiments to be explored earlier through a practical scale-down approach.
With its expanded product portfolio, Leadgene Biosolutions enters its next phase with a clearer and more focused offering—supporting earlier, data-driven decisions in biopharmaceutical development and enabling long-term metabolic insight for discovery research.
